---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-054504"
form_type: "8-K"
ticker: "ALKS"
cik: "0001520262"
company_name: "Alkermes plc."
filed_at: "2023-10-23T23:59:59+00:00"
generated_at: "2026-06-09T16:36:32.913745+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Alkermes reports Phase 1 data for ALKS 2680 showing significant sleep latency improvement in narcolepsy type 1

## Summary
- ALKS 2680 demonstrated dose-dependent improvement in sleep latency: +18, +30, +37 minutes vs placebo (-1 min) at 1, 3, 8 mg (p<0.01 to p<0.001).
- At 8 mg dose, patients maintained wakefulness for full 40-minute MWT up to 10 hours post-dose.
- ALKS 2680 generally well tolerated; mild AEs at 8 mg (insomnia, pollakiuria, salivary hypersecretion); no serious AEs.
- PK profile supports once-daily oral dosing; Phase 2 study planned for H1 2024.
- First cohort (4 NT1 patients) data presented at World Sleep Congress; study also enrolling NT2 and IH patients.

## SEC filing metadata
- accession: 0000950170-23-054504
- form_type: 8-K
- ticker: ALKS
- cik: 0001520262
- company_name: Alkermes plc.
- filed_at: 2023-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1520262/000095017023054504/0000950170-23-054504-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1520262/000095017023054504/alks-20231023.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-054504
- JSON: https://secwatch.observer/filing/0000950170-23-054504.json
- Plain text: https://secwatch.observer/filing/0000950170-23-054504.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.